Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
15 hedge funds and large institutions have $145K invested in Seelos Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.
12% more capital invested
Capital invested by funds: $129K → $145K (+$15.8K)
17% less funds holding
Funds holding: 18 → 15 (-3)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$71.8K |
| 2 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$54.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$48.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$11 |
| 5 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$32.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.64K |
| 3 |
Morgan Stanley
New York
|
-$4.12K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$838 |
| 5 |
BlackRock
New York
|
-$471 |
SEEL Hedge Fund Activity: Q3 2024 in Review
15 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2024, worth a combined $145K — up 12% from $129K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SEEL and 1 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was AdvisorShares Investments, adding an estimated $71.8K. The largest seller was Wealth Effects, exiting entirely with an estimated $32.1K sold.
- 15 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2024, down from 18 in Q2 2024.
- Funds reported $145K of Seelos Therapeutics, Inc. Common Stock stock for Q3 2024, up 12% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2024 and 4 closed out, a net change of -3 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2024 was AdvisorShares Investments, an estimated $71.8K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2024 was Wealth Effects, an estimated $32.1K sold.
Based on aggregated 13F filings for Q3 2024.